As personalized medicine is currently gaining popularity, our findings for crizotinib may contribute to effective prescriptions to prevent further development of drug-resistant cancer in lung cancer patients who have c-MET and ALK mutation phenotypes. This evidence concerns the gene MET and lung carcinoma.